|
|
Dan Yang, Ying Zhang, Hao G. Nguyen, Milka Koupenova, Anil K. Chauhan, Maria Makitalo, Matthew R. Jones, Cynthia St. Hilaire, David C. Seldin, Paul Toselli, Edward Lamperti, Barbara M. Schreiber, Haralambos Gavras, Denisa D. Wagner, Katya Ravid
J Clin Invest. 2006;
116(7):1913
doi:10.1172/JCI27933
Abstract |
Full text
| PDF
| Supplemental material

A
denosine has been described as playing a role in the control of inflammation, but it has not been certain which of its receptors mediate this effect. Here, we generated an A2B adenosine receptor–knockout/reporter gene–knock-in (A2BAR-knockout/reporter gene–knock-in) mouse model and showed receptor gene expression in the vasculature and macrophages, the ablation of which causes low-grade inflammation compared with age-, sex-, and strain-matched control mice. Augmentation of proinflammatory cytokines, such as TNF-α, and a consequent downregulation of IκB-α are the underlying mechanisms for an observed upregulation of adhesion molecules in the vasculature of these A2BAR-null mice. Intriguingly, leukocyte adhesion to the vasculature is significantly increased in the A2BAR-knockout mice. Exposure to an endotoxin results in augmented proinflammatory cytokine levels in A2BAR-null mice compared with control mice. Bone marrow transplantations indicated that bone marrow (and to a lesser extent vascular) A2BARs regulate these processes. Hence, we identify the A2BAR as a new critical regulator of inflammation and vascular adhesion primarily via signals from hematopoietic cells to the vasculature, focusing attention on the receptor as a therapeutic target.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(70)
| Title and authors |
Publication |
Year |
Adenosine A2A Receptor Upregulation in Human PMNs Is Controlled by miRNA-214, miRNA-15, and miRNA-16 :
Jens Heyn, Carola Ledderose, Ludwig C. Hinske, Elisabeth Limbeck, Patrick Möhnle, Holger A. Lindner, Simone Kreth
|
Shock
|
2012 |
Purines as potential morphogens during embryonic development
Karine Massé, Nicholas Dale
|
Purinergic Signalling
|
2012 |
Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice
Jessica D. Bauerle, Julee H. Dalton, Douglas Ridyard, Alexander Badulak, Eunyoung Tak, Eóin N. McNamee, Eric Clambey, Radu Moldovan, German Reyes, Almut Grenz
|
J. Clin. Invest.
|
2012 |
Targeting adenosine receptors in the development of cardiovascular therapeutics
Niels P Riksen, Gerard A Rongen
|
Expert Rev. Clin. Pharmacol.
|
2012 |
Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors
Fernanda Rocha Lapa, Morgana Duarte Silva, Daniela Almeida Cabrini, Adair R. S. Santos
|
Purinergic Signalling
|
2012 |
Adenosine and its receptors in the heart: Regulation, retaliation and adaptation
John P. Headrick, Jason N. Peart, Melissa E. Reichelt, Luke J. Haseler
|
Biochimica et Biophysica Acta (BBA) - Biomembranes
|
2011 |
Advances in Pharmacology
Michael Koeppen, Tobias Eckle, Holger K. Eltzschig
|
Pharmacology of Purine and Pyrimidine Receptors
|
2011 |
Adenosine and blood platelets
Hillary A. Johnston-Cox, Katya Ravid
|
Purinergic Signalling
|
2011 |
Advances in Pharmacology
Stefania Gessi, Stefania Merighi, Katia Varani, Pier Andrea Borea
|
Pharmacology of Purine and Pyrimidine Receptors
|
2011 |
Advances in Pharmacology
Igor Feoktistov, Italo Biaggioni
|
Pharmacology of Purine and Pyrimidine Receptors
|
2011 |
|